A novel Leishmania infantum nuclear phosphoprotein Lepp12 which stimulates IL1-beta synthesis in THP-1 transfectants
© Fragaki et al; licensee BioMed Central Ltd. 2003
Received: 7 February 2003
Accepted: 30 April 2003
Published: 30 April 2003
We report cloning and characterization of a novel Leishmania infantum protein which we termed Lepp12, and we examine its possible implication in the interference with intramacrophage signaling pathways.
The protein Lepp12 contains 87 amino acid sequence and exhibits 5 potential phosphorylation sites by protein kinase C (PKC). Recombinant GST-Lepp12 is phosphorylated in vitro by exogenous PKC and by PKC-like activities present in promastigote and in the myelomonocytic THP-1 cell line, indicating that at least one phosphorylation site is functional on the recombinant Lepp12. The natural Lepp12 protein is present in L. infantum promastigotes, as evidenced using specific anti-Lepp12 antibodies produced by immunopurification from acute phase VL patient sera. Interestingly, human patient sera are strongly reactive with GST-Lepp12, demonstrating immunogenic properties of Lepp12 in man, but no immune response to Lepp12 is detectable in experimentally infected animals. When isolated from promastigotes, Lepp12 migrates as two species of apparent MW of 18.3 kDa (major) and 14 kDa (minor), localizes in the nuclear fraction and appears constitutively phosphorylated. Natural Lepp12 is phosphorylable in vitro by both exogenous PKC and PKC-like activity present in THP-1 extracts. The intracellular Lepp12 transfected into THP-1 cells activates these cells to produce IL-1beta and induces an enhancing effect on PMA stimulated IL-1beta synthesis, as demonstrated using GST-Lepp12 transfectants.
Together these results indicate that Lepp12 represents a substrate for PKC or other PKC-like activities present in the promastigote form and the host cell and therefore may interfere with signal transduction pathways involving PKC.
Leishmaniases are parasitic diseases due to protozoa of the genus Leishmania transmitted by sandflies of the genus Phlebotomus. In the vertebrate host,Leishmania live in macrophages as obligate intracellular amastigotes, and as flagellated free promastigotes in the intestine of the sandfly vector. There are at least 20 different species of Leishmania parasites causing a wide spectrum of human diseases, ranging in severity from spontaneously healing skin lesions to fatal visceral leishmaniasis [1, 2]. The prevalence of the disease worldwide is estimated to be 12 million cases and an incidence of 500 000 new cases of visceral and 1 500 000 of cutaneous disease has been reported . Patent visceral leishmaniasis (VL) caused by L. infantum (L. chagasi) is a fatal infection when left untreated . There is an increasing incidence of the disease in HIV-infected individuals in southern Europe, [3, 4] and post-therapeutically, in organ transplantation . This is due, in part, to the reactivation of latent Leishmania in persons presenting immunosuppressed conditions . Indeed, in endemic regions the existence of asymptomatic Leishmania carriers has been documented [6, 7] and in successfully treated VL patients the currently available drugs do not result in the complete elimination of the parasite.
Leishmania parasites developed various strategies to overcome the protection provided by the immune system of the host [for review [8, 9]]. In particular, phosphorylation reactions have been shown to participate in several ways in escape mechanisms, at different levels of the parasite-host interaction. For instance, a protein kinase isolated from L. major (LPK-1) is able to phosphorylate components of the human complement system (C3, C5 and C9) leading to its inactivation . Intracellular Leishmani a amastigotes, not only adapt to phagolysosomal low pH (5.5) and high temperature (37°C) in order to survive in the host cells [11, 12], but also induce functional modifications in macrophages. These include decrease in cytokine production, inhibition of oxydative burst activity, alteration of antigen presentation, and of expression of MHC class II molecules. This ability of Leishmani a to inhibit macrophage effector activities, also termed deactivation [8, 13], may result from a direct interference of leishmanial molecules with macrophage signal transduction pathways. In particular, inhibition of macrophage protein kinases such as protein kinase C (PKC) [14–16] and Janus kinases [17, 18], as well as alteration of stimulus-induced intracellular calcium gradient and decreased production of inositol 1, 4, 5-triphosphate [19, 20] have been reported. The inhibition of PKC-depending signaling by Leishmania is well documented, and the effect can be ascribed in part to the properties of lipophosphoglycan (LPG) [21–28].
In this paper we report cloning and characterization of a novel L. infantum protein termed Lepp12, the predicted aminoacid sequence of which contains 5 potential sites of phosphorylation by PKC and examine its possible implication in the interference of intramacrophage signaling pathways.
Cloning of a novel L. infantum cDNA and production of recombinant protein GST-Lepp12
Identification and localization of the natural Lepp12 in L. infantum
In vitro phosphorylation of recombinant Lepp12
Phosphorylation of natural Lepp12 protein
Phosphorylation of the recombinant and the natural Lepp12 by lysate of THP-1 cells
Effect of Lepp12 on IL-1beta production by THP-1 cells
In this paper we report the cloning and characterization of a novel L. infantum protein termed Lepp12. The 267 nucleotide long ORF was identified by screening a L. infantum cDNA library with an acute phase VL patient serum. The deduced 87 aminoacid sequence corresponds to a 11.6 kDa hydrophile, positively charged, protein with no homology with L. infantum protein sequences reported to date. Interestingly, Lepp12 exhibits 5 potential phosphorylation sites for protein kinase (PKC) and one N-glycosylation site. The fusion protein produced in E. coli and purified by glutathione-sepharose affinity chromatography showed by SDS-PAGE analysis one major band at the expected M.W. (38.5 kDa) and at least one smaller M.W. component at 34 kDa. As previously reported , partial proteolysis occurring during production in E. coli is likely to account for this phenomenon.
The purified fusion protein was used as capture antigen for evaluating the anti-Lepp12 antibody response in human with VL as well as in experimentally infected mouse and hamster. All patients tested were treated, following the clinical and parasitological diagnosis. Patients with obvious VL but not LST positive asymptomatic individuals showed at diagnosis anti-Lepp12 reactivity by ELISA or Western blotting (WB) which gradually declined following successful therapy resulting in clinical cure. Of note, VL patients serum samples recognized the low MW fusion protein compound in WB analysis thus supporting the Lepp12-like nature of this component. Conversely, anti-Lepp12 antibodies were undetectable by ELISA in experimentally infected mouse or hamster and attempts to prepare anti-Lepp12 antiserum in these animals by immunization with DNA encoding Lepp12 protein or purified GST-Lepp12 were either unsuccessful or resulted in low titers immune sera, respectively. Consequently, immunopurified human anti-Lepp12, obtained by passage of E. coli-absorbed VL patient serum sample unto GST-Lepp12-coated latex column, were used as source of anti-Lepp12 antibody for the following experiments. This antibody preparation was shown to specifically detect by WB analysis the 38.5 kDa fusion protein as well as the low MW compound and was used to detect natural Lepp12 in crude promastigote preparation and in nuclear extract.
The species-specific humoral reactivity to Lepp12 deserves a comment. The fact that in infection of species other than human, the anti-Lepp12 antibody response was undetectable, while in human VL patients the response was detectable only at low serum dilutions, indicates that Lepp12 behaves as a weak immunogen, in contrast to papLe22. Moreover, the lack of a notable antibody response following extensive immunization of hamster, suggests existence of anti-Lepp12-repertoire or Lepp12-processing/presentation deficiencies in this and other animal laboratory species. Taken together, if one considers that Lepp12 is a weak immunogen, it is not surprising that only the most potent immune system can mount a detectable antibody response. Indeed, high responder character of human immune system to Leishmania proteins has been already emphasized, since anti-promastigote antibody responses measured in patients with VL exceeded by far those obtained with experimentally infected mouse or hamster or naturally infected dogs .
Natural endogenous Lepp12 appeared under two molecular entities migrating with apparent MW of 18.3 kDa and 14 kDa, the former being more represented. This discrepancy with the expected MW derived from the amino acid analysis can be explained by the occurrence in the promastigote Lepp12 of different glycosylation and/or phosphorylation states, the latter being known to modify the electrophoretic mobility of proteins . Nevertheless, as reported earlier , the occurrence in promastigote fraction of two cross reactive entities with different MW cannot be totally excluded. In addition, there are three features indicating that tLepp12 could belong to the p14 and p18 nuclear fractions that we have previously reported . First, the anti-Lepp12 antibodies recognize two bands of similar molecular weight to p14 and p18 fractions, second, p14 and p18 antigens share common epitopes and.third, Lepp12, p14 and p18 are all nuclear proteins. Finally, using RT-PCR Lepp12 mRNA was also detectable in amastigote, thus indicating that Lepp12 is likely to be present during parasite replication in host cell.
Amino acid sequence analysis of Lepp12 demonstrated 5 potential phosphorylation sites for PKC. In order to verify the functionality of these sites, several in vitro phosphorylation experiments were performed using as target either the fusion protein or immunocaptured natural Lepp12. GST-Lepp12 was phosphorylated in vitro by exogenous PKC and by PKC-like activities present in promastigote and in the myelomonocytic THP-1 cell line. These results indicate that at least one functional phosphorylation site is present on the recombinant Lepp12. In the same way, natural Lepp12, when immunoprecipitated, appeared to be also phosphorylated by both exogenous PKC and PKC-like activity present in THP-1 extracts. In promastigote, natural Lepp12, which was shown to localize in the nuclear fraction, appears under a constitutive phosphorylated state. Although there is not yet a direct proof, such as the natural protein sequencing or knock out experiments, of the identity of the Lepp12 ORF isolated from the library and the antigens recognized in the nuclear extracts, our data, brought to light in a logical sequence, provide a number of strongly converging indications for such identity. First, the recombinant Lepp12 (rLepp12) is phosphorylated in several in vitro assays. Second, a natural protein is recognized and localized in promastigote nuclear extract using antibodies affinity purified on rLepp12. Third, this natural protein is phosphorylated in the same vitro assays. Finally, this natural protein immunoprecipitated from promastigote nuclear extract is shown to be constitutively phosphorylated. There is an as yet unanswered question, namely whether and how does Lepp12 reach the host cell cytoplasm. At the present stage of our study we can hypothesize that Lepp12, being a protein strongly charged by positive residues, is able to cross membranes and to migrate in various compartments in a manner analogous to that of the TAT protein of HIV . An additional, not exclusive, possibility is that Lepp12 presence in the host cell cytoplasm results from parasite destruction. A question, which seems related to this one, and to which there is no as yet a clear answer, is by which mechanisms the parasite nuclear proteins such as histones or papLe22 elicit strong immune responses in the vertebrate host. The concept of widely distributed antigens called panantigens with prominent immunogenicity addressed by Requena and collaborators  may answer this question.
Together our results indicate that the natural Lepp12 represents a substrate for PKC or other PKC-like activities or for phosphatase activities present in the promastigote and the host cell and therefore may interfere with signal transduction pathway involving PKC. This assumption was in part supported by the data obtained using transfection experiments. Indeed, unstimulated and PMA-stimulated GST-Lepp-12-transfected THP-1 cells produced markedly more IL-1beta than untransfected and GST-transfected controls whereas LPS-induced cytokine remained in all cases unchanged. These results indicate that in our in vitro model, Lepp12 interferes specifically with IL-1beta production dependent on PMA induced signaling pathway. The relevance of these findings lays in the crucial role played by IL-1beta as a main pro-inflammatory cytokine and as a main co-stimulatory factor of primary T-cell activation .
Several questions arising about Lepp12-transfected THP-1 cells are of relevance in order to better understand the role of Lepp12 in the host parasite interaction. First, does the presence of Lepp12 result in an increased transcription of the IL-1 gene and in this case, which are the IL-1 transcription factors that are modulated? Our observations showing that a Leishmania protein can be a putative macrophage activator are reinforced by a recent report  showing that L. major activates IL-1alpha gene transcription in macrophage cell line. Next, at what level of the signal transduction pathway is implicated the effect of Lepp12? Whether Lepp12 interferes with PKC directly or the downstream phosphorylation cascade leading to macrophage activation remains to be determined. Alternatively, Lepp12 under its phosphorylated form may inactivate phosphatases thus enhancing protein kinase activities involved in macrophage activation. These two hypotheses are of prime importance in the context of the parasite/host cell interaction. Indeed, invasion of macrophage by L. infantum or other Leishmania spp. was repeatedly reported to lead to a general deactivation of host cell with most genes being down regulated. This macrophage impairment following parasite entry includes innate and cell-mediated immune response such as phagocytosis , nitric oxide generation  and IL-12 production  and results in increased parasite survival inside the host cell [8, 9]. A variety of mechanisms potentially contributing to macrophage deactivation during intracellular infection have been identified and among these, disruption of important target cell functions through interference with signal transduction is well documented. For example, infection with L. donovani selectively attenuates the IFNgamma-activated Jak-Stat1 pathway , reduces PMA-induced PKC activity  and impairs PKC-induced c-fos expression  or stimulates phosphotyrosine phosphatase SHP-1 . On the contrary, L. donovani attachment was shown to stimulate PKC-mediated oxidative events in bone-marrow derived macrophages  and glycosylphosphatidylinositol of L. mexicana were found to activate PKC and protein tyrosine kinases in RAW 264 cells . In this context Lepp12 appears, at least in our in vitro model, rather as a putative PKC enhancer. It also remains to be examined how our observations on the effect of Lepp12 on THP-1 activability can be translated to more physiological systems, in particular to Lepp12-transfected macrophages? Does Lepp12 impairs macrophage functions such as nitric oxide production? Finally, one should understand how an activation of one gene  or even of a series of genes by a protein can be integrated in the complex situation which occurs following parasite entry and which results in the global host cell deactivation. Indeed, it may be possible that during infection which involves numerous and complex amastigote antigens/host cell interactions, Lepp12 behaves quite differently and participates to the disruption of the protein kinase/protein phosphatase homeostatis leading to macrophage impairment.
Cell cultures and cell preparations
The promastigote form of L. infantum MON-1 (MHOM/FR/94/LPN101) was cultured in a complete RPMI medium at 25°C under usual conditions , except in some experiments indicated in the text where Fetal Calf Serum (FCS) was substituted by 0.1 % BSA. Early stationary phase promastigotes (5-day-old cultures) were used to carry out various cell preparations, unless indicated otherwise in figure legends, and were washed 3 times by sedimentation at 206 g for 5 min at 4°C in PBS containing 1 mM NaVO4. For western blot analyses promastigotes were lysed in an electrophoresis buffer previously heated at 100°C for 10 min (100 mM Tris pH 6.8, 3 % SDS, 12.5 % glycerol). Promastigote lysates used to stimulate phosphorylation of recombinant Lepp12 were obtained as supernatants of centrifugation at 20,600 g for 15 min at 4°C after lysis of PBS-washed cells for 30 min at 4°C in water containing 1% NP40, 1 mM NaVO4, 25 mM beta-glycerophosphate, 50 microM NaF, 2.5 mM NaPPi and 1 tablet (per 1 ml) of complete protease-inhibitor-cocktail (Roche, Meylan France). Nuclear extracts were prepared as follows: washed promastigote pellet was incubated for 10 min on ice in 0.5 ml of lysis buffer 1 (Hepes 10 mM, pH 7.5, MgCl2 1.5 mM, KCl 10 mM, DTT 0.5 mM, NP40 0.5 %, supplemented with proteases and phosphatases inhibitors as above), centrifuged (1,460 g, 10 min, 4°C), and the resulting pellet was incubated for 20 min on ice with 0.1 ml of lysis buffer 2 (Hepes 200 mM, pH 7.5, MgCl2 1.5 mM, KCl 840 mM, DTT 0.5 mM, glycerol 25%, EDTA 0.2 mM, supplemented with proteases ans phosphatases inhibitors). After centrifugation (15,500 g, 15 min, 4°C), the resulting supernatant was recovered. For immunoprecipitation experiments 0.1 ml of nuclear extract was first incubated with 23 microL of immunopurified anti-Lepp12 antibodies (or control, irrelevant human antibodies) for 5 h at 4°C under gentle agitation, then after adding 20 microL settled volume of mixed (1:4, v/v) protein A sepharose/sepharose 4B, incubation continued overnight as before. After centrifugation (20,600 g, 2 min, 4°C), 100 microL of 4X electrophoresis buffer supplemented with 16% betaME was added to the resulting pellet or the pellet was used in phosphorylation experiments (see below). The amastigote form used to prepare RNA was purified from hamster spleen . Human monocytic cell line THP-1 was cultured in a complete RPMI medium and cell lysates used to stimulate phosphorylation of the recombinant and the natural Lepp12 were prepared as described above. The protein content in all cell preparations was measured using the Micro BCA Protein Assay Reagent kit, following supplier's (Pierce, Perbio, Bezons France) recommendations.
Screening of cDNA libraries
Two libraries of L. infantum promastigote cDNA (synthesized with oligodT primer or random hexaprimers) in lambda-gt11 bacteriophage were kindly provided by Dr. Carlos Alonso (Madrid). Approximately 105 lambda-gt11 plaques were screened for each library, using an acute-phase patient serum as previously described .
PCR amplifications, cloning and sequencing
For cDNA synthesis, total RNA from 5.108 L. infantum promastigotes and 5.107 L. infantum amastigotes was extracted with 600 microL RLT lysis buffer (Quiagen, Courtaboeuf, France) following manufacturer's instructions and quantitated by spectrophotometry analysis. 2.5 μg RNA were reverse transcribed as previously described . All PCR reactions were carried out using 0.2 mM deoxynucleoside, 1 microM of each primer and 0.014 U/microL of thermostable DNA polymerase (Q-biogene, Illkirch, France), in a final volume of 25 microL lambda gt11 inserts corresponding to the positive clones were amplified by PCR using specific phage primers and sequenced as previously described . Specific primers were chosen for the clone termed 12 K and the total sequence of the coding region was obtained by RACE (Rapid Amplification of cDNA Ends)-PCR using high fidelity PWO polymerase (Boehringer Mannheim) and 5 microL L. infantum cDNA, as described previously (42). Briefly, the amplification of the 3' end of 12K cDNA was obtained with the specific primer F and the oligoT primer containing SalI site and its 5' end was obtained with the specific primer R and the "mini-exon" primer  with EcoRI site (underlined) 5'-TAGGGATCC AACTAAGCGTATATAAGTATCAGTTT-3'. After sequencing of 5' and 3' ends, the coding region corresponding to the clone 12K was amplified from L. infantum promastigote and amastigote cDNAs, using PWO polymerase and two specific primers F and R containing EcoRI and SalI sites, respectively. The clone 12K is termed thereafter Lepp12.
Expression and purification of recombinant proteins
PCR amplified coding region of Lepp12 (Lepp12-ORF) and pGEX-6P-1 vector (Amersham Pharmacia Biotech, Orsay, France) were digested with an excess of EcoRI and SalI (Biolabs Ozyme, Saint Quentin, France) restriction enzymes. The ligation between pGEX-6P-1 and Lepp12-ORF and the expression of the fusion protein with glutathione S-transferase (GST) in E. coli BL21 were performed as previously described . The purification of GST-Lepp12 was done essentially as recommended by the supplier (Bulk GST Purification Module, Pharmacia). Briefly, the recombinant bacteria were harvested, washed once in NaCl 0.9% by sedimentation at 2500 g for 15 min at 4°C, resuspended in 1:20 volume of PBS containing protease inhibitors (complete protease-inhibitor-cocktail, Roche) and lysed by two sonication cycles of 10 seconds. After solubilization with 1% Triton X-100, the fusion protein GST-Lepp12 was adsorbed to glutathione-Sepharose gel (50% in PBS) for 30 min. After incubation, in order to obtain material without bacterial contamination, 10 washes with 10 volumes of PBS were carried out and the fusion protein was then eluted either using reduced glutathione 20 mM (in Tris-HCl 50 mM buffer pH 8) or with SDS 0.1%. Purified material was analyzed by SDS-PAGE (14% polyacrylamide gel), after staining with Coomassie G-250 stain (Invitrogen). E. coli BL21 transformed with pGEX-6P-1 vector without Lepp12-ORF were treated similarly, and the resulting recombinant GST was purified in parallel. E. coli BL21 not transformed were also treated similarly. For phosphorylation experiments (see below), the fusion proteins GST-Lepp12 and GST were used in a form adsorbed on the glutathione-Sepharose gel and were maintained in Assay Dilution Buffer (20 mM MOPS, pH 7.2, 25 mM beta-glycerophosphate, 1 mM sodium orthovanadate, 1 mM dithiotreitol, 1 mM CaCl2). E. coli BL21 proteins adsorbed non specifically on glutathione-Sepharose gel, were used as additional controls.
The time course of specific anti-Lepp12 IgG levels in VL patient sera was determined by a classical enzyme-linked immunosorbent assay (ELISA) procedure analogous to that described previously for antileishmanial antibody determination . Briefly, GST-Lepp12, or control GST, was coated overnight at 1 microg/ml (50 microL), the sera were tested at 1:100 dilution, and revealed with anti-human IgG peroxidase-conjugate used at 1:2000 dilution. Sera from leishmanin skin test (LST) negative subjects were used controls and resulted in OD values below 0.1. Incubation steps were performed in 0.1 M phosphate buffer pH 7.2 containing 1% (wt/vol) skimmed dry milk, 0.12% (vol/vol) Triton X-100, 0.2% (vol/vol) chloroform, 0.02% Thimerosal, 100 microg phenol red/ml.
Production of immunopurified anti-Lepp12 antibody
Anti-Lepp12 antibodies were immunopurified from sera of VL patients in acute phase of VL on a GST-Lepp12-coated column. Briefly, 40 microg of GST-Lepp12 were coated on 200 microL of (2 times PBS-washed) Latex (Styrene divinylbenzene, 90.7 micron, Sigma), by overnight incubation at 25°C. The Lepp12-coated latex beads were mixed with 1 ml of sephadex gel G-25 (Pharmacia, France) and poured into a 2 ml column. The column was extensively washed with PBS and 0,1 M HCl-Glycine buffer pH 2,6 containing 0.5 M NaCl. VL patient serum (2 ml), previously absorbed with 0.5 ml of E. coli lysate, was loaded into the column. The column was washed in PBS and bound antibodies were eluted with the HCl-glycine buffer. After neutralization with 1 M Tris solution, concentration against dry PEG 35000 and dialysis with PBS, the antibody solution was supplemented with 2 mg/ml BSA filtrated on 0.22 micron millipore membrane and stored at 4°C. Typically 20 microg of immunopurified antibody were obtained from 1 ml of serum and was stored at 40 microg/ml concentration.
Western blot analysis
Approximately 5 microg of the recombinant protein (GST-Lepp12 or GST) purified from a bacterial culture as described above, or 40 microg of total leishmanial proteins , were loaded per well of SDS-14 % polyacrylamide gel (mini-protean II cell, ref Bio-Rad) and electrotransferred to nitrocellulose (minitransblot cell, Bio-Rad) as previously described [29, 33]. Patient and control (from LST negative subjects) sera were used at 1:50 and 1:100 dilutions and peroxidase-conjugates directed against human immunoglobulin G (Sigma Illkrich, France) were used at 1:100 and 1:1000 dilution, respectively. To reveal immunopurified anti-Lepp12 antibody, prepared as described above and used at 1:8, peroxidase-conjugates directed against human IgG were used at 1:500. Enzymatic activity was revealed with 1.5 mM diaminobenzidine, 0.38 mM CoCl2, 0.03 % H2O2 in PBS. Alternatively, 120 microg (in 30 microL) of leishmanial proteins were loaded per well of mini-gel and electrotransferred to nitrocellulose membrane, as above. After saturation (10 mM Tris-HCl pH 7.4, 3 % BSA (Sigma, Illkrich, France), 150 mM NaCl, 1 mM EDTA, 0.1 %, Tween, 0.5 % Gelatine) for 2 h at 4°C, nitrocellulose was incubated with 0.25 mg/ml of anti-P-Ser/P-Thr antibody (Cliniscience, Montrouge France) for 18 h at 4°C, washed 3 times (1 % TBS-NP40, 10 min), then saturated again. Anti-rabbit immunoglobulin (IgG) peroxidase conjugate (Dako, Trappes, France) was used at 1:10000 dilution (1 h in saturation buffer). Enzymatic activity was revealed with ECL kit (Enhance Chemiluminescence, Amersham Pharmacia Biotech, Orsay, France) as recommended by the supplier on a sensitive photographic MP-hyperfilm (Amersham, Orsay, France). The quality of the transfert on nitrocellulose was regularly checked and confirmed by gel staining with Coomassie G-250 stain (Invitrogen, Netherland) and nitrocellulose membrane staining with Amido-Black.
In vitro phosphorylations
Experiments were carried out with recombinant GST-Lepp12 or immunoprecipitated native Lepp12 and histone mix from bovine calf thymus (Upstate Biotechnology, Euromedex France, reference number14-155) as positive control and GST and BL21 lysate as negative controls, in accordance with the protocol supplied in PKC assay kit (Upstate Biotechnology, Euromedex France). Briefly, different proteins (10 microg) were incubated for 10 min at 30°C in the presence of 10 microCi gamma-P32 ATP (ICN) in Assay Dilution Buffer (ADB) with sonified (90 sec) protein kinase C lipid activator, and with 25 ng exogenous PKC (Upstate Biotechnology, Euromedex, Mundolsheim, France) or 15 microg of promastigote lysate or THP-1 lysate prepared as described above. The reaction was stopped by addition of electrophoresis buffer, and the samples were electrophorezed and electrotransferred to nitrocellulose membrane. Phosphorylated material was revealed by autoradiograpy as described above. Exposition times are indicated in figure legends.
Transfection of recombinant GST-Lepp12 into THP-1 cells
The transfection of the recombinant GST-Lepp12 protein into THP-1 cells was carried out using Chariot Transfection Kit (Active Motive, Rixensart, Belgium) following the manufacturer's instruction manual. Briefly, 3 × 105 cells were seed in 3 ml of complete medium per well of a 6-well plate and cultured in usual conditions. After 48 h of culture, 200 microL of Chariot-protein complex (see below) was overlaid on the pellet of twice-washed THP-1 cells, and 400 microL serum-free medium was added to the overlay to achieve the final transfection volume of 600 microL. After incubation at 37°C for one hour, 1 ml of complete growth medium was added to the cells and incubation was allowed to continue for 2 more hours. The transfected cells were then used for activation experiments. The Chariot-protein complex formation was achieved by incubation of 100 microL protein dilution (2 microg of protein (GST or GST-Lepp-12) in 100 microL of PBS) with the 100 microL Chariot dilution (6 microL of Chariot in 100 microL of sterile water) at room temperature for 30 minutes.
Cell activation and cytokine assays
In order to assess the potential presence of endotoxin-like material in GST and GST-Lepp12 preparations selected for the transfection experiments, THP-1 cells were cultured at 2.5 × 105/ml in the presence of various concentrations of both proteins for 24 h at 37°C in standard conditions. Culture wells were extracted with 9 mM CHAPS detergent and assayed for IL-1beta production by sandwich ELISA as previously reported . The threshold sensitivity of the ELISA was 10 pg/ml and the technique was shown to quantify equally well the mature secreted and the intracellular forms of the cytokine. GST-transfected, GST-Lepp12-transfected and untransfected THP-1 cells (at 3.75 × 105 cells/ml) were challenged with various concentrations of phorbol-12-myristate 13-acetate (PMA, 0.1–10 ng/ml) or LPS (0.1–10 microg/ml) or left unstimulated. Culture wells were extracted and IL-1beta was quantified as described above.
Nucleotide sequence accession number
The Lepp12 cDNA sequence obtained in this study has been assigned GenBank accession number AF540954.
This work was supported by grants from the Ministry of Education and Research (EA2675) and by gifts from le Groupe d'Action Contre la Leishmaniose (GACL). KF is recipient of an Award from La Fondation Marcel Bleustein-Blanchet pour la Vocation, and of fellowships from La Fondation pour la Recherche Médicale and from l'Association des Femmes Françaises des Universités. We thank Dr. Y. Le Fichoux (Laboratoire de Parasitologie Mycologie, Hôpital de l'Archet, Nice) for providing us with VL patients sera, Roger Grattery and Aurore Grima for performing illustration work, Gilbert Dabbene for taking care of the animal facility, and Sadia Boucherak for administrative assistance.
- Desjeux P: UNAIDS: Leishmania and HIV in gridlock. Division of Control of Tropical Diseases, World Health Organization, Geneva, Switzerland. 1998
- Pearson RD, Sousa QA: Clinical spectrum of leishmaniasis. Clin Infect Dis. 1996, 22: 1-13.View ArticlePubMed
- Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J: Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997, 10: 298-319.PubMed CentralPubMed
- Kubar J, Marty P, Lelièvre A, Quaranta JF, Staccini P, Caroli-Bosc C, Le Fichoux Y: Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS. 1998, 12: 2147-2153. 10.1097/00002030-199816000-00009.View ArticlePubMed
- Dedet JP, Pratlong F: Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents. J Eukaryot Microbiol. 2000, 47: 37-39.View ArticlePubMed
- Kubar J, Quaranta JF, Marty P, Lelievre A, Le Fichoux Y, Aufeuvre JP: Transmission of L. infantum by blood donors. Nat Med. 1997, 3: 368-View ArticlePubMed
- Le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelièvre A, Marty P, Suffia I, Rousseau D, Kubar J: Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol. 1999, 37: 1953-1957.PubMed CentralPubMed
- Bogdan C, Gessner A, Solbach W, Rollinghoff M: Invasion, control and persistence of Leishmania parasites. Curr Opin Immunol. 1996, 8: 517-525. 10.1016/S0952-7915(96)80040-9.View ArticlePubMed
- Mauel J: Intracellular survival of protozoan parasites with special reference to Leishmania spp., Toxoplasma gondii and Trypanosoma cruzi. Adv Parasitol. 1996, 38: 1-51.View ArticlePubMed
- Hermoso T, Fishelson Z, Becker SI, Hirschberg K, Jaffe CL: Leishmanial protein kinases phosphorylate components of the complement system. EMBO J. 1991, 10: 4061-4067.PubMed CentralPubMed
- Bates PA: Axenic culture of Leishmania amastigotes. Parasitol Today. 1993, 9: 143-146. 10.1016/0169-4758(93)90181-E.View ArticlePubMed
- Zilberstein D, Shapira M: The role of pH and temperature in the developement of Leishmania parasites. Annu Rev Microbiol. 1994, 48: 449-470. 10.1146/annurev.mi.48.100194.002313.View ArticlePubMed
- Reiner NE: Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection. Immunol Today. 1994, 15: 374-381. 10.1016/0167-5699(94)90176-7.View ArticlePubMed
- Bhattacharyya S, Ghosh S, Jhonson PL, Bhattacharya SK, Majumdar S: Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events. Infect Immun. 2001, 69: 1499-1507. 10.1128/IAI.69.3.1499-1507.2001.PubMed CentralView ArticlePubMed
- Brandonisio O, Panaro MA, Sisto M, Acquafredda A, Fumarola L, Leogrande D: Interactions between Leishmania parasites and host cells. Parassitologia. 2000, 42: 183-190.PubMed
- Ghosh S, Bhattacharyya S, Das S, Raha S, Maulik N, Das DK, Roy S, Majumdar S: Generation of ceramide in murine macrophages infected with Leishmania donovani alters macrophage signaling events and aids intracellular parasitic survival. Mol Cell Biochem. 2001, 223: 47-60. 10.1023/A:1017996609928.View ArticlePubMed
- Nandan D, Reiner NE: Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: selective inhibition of signaling through Janus kinases and Stat1. Infect Immun. 1995, 63: 4495-4500.PubMed CentralPubMed
- Prive C, Descoteaux A: Leishmania donovani promastigotes evade the activation of mitogen-activated protein kinases p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase-1/2 during infection of naive macrophages. Eur J Immunol. 2000, 30: 2235-2244. 10.1002/1521-4141(2000)30:8<2235::AID-IMMU2235>3.0.CO;2-9.View ArticlePubMed
- Olivier M, Brownsey RW, Reiner NE: Defective stimulus-response coupling in human monocytes infected with Leishmania donovani is associated with altered activation and translocation of protein kinase C. Proc Natl Acad Sci. 1992, 89: 7481-7485.PubMed CentralView ArticlePubMed
- Olivier M, Baimbridge KG, Reiner NE: Stimulus-response coupling in monocytes infected with Leishmania. Attenuation of calcium transients is related to defective agonist-induced accumulation of inositol phosphates. J Immunol. 1992, 148: 1188-1196.PubMed
- Corradin S, Mauel J, Ransijn A, Sturzinger C, Vergeres G: Down-regulation of MARCKS-related protein (MRP) in macrophages infected with Leishmania. J Biol Chem. 1999, 274: 16782-16787. 10.1074/jbc.274.24.16782.View ArticlePubMed
- Descoteaux A, Matlashewski G, Turco SJ: Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania lipophosphoglycan. J Immunol. 1992, 149: 3008-3015.PubMed
- Giorgione JR, Turco SJ, Epand RM: Transbilayer inhibition of protein kinase C by the lipophosphoglycan from Leishmania donovani. Proc Natl Acad Sci USA. 1996, 93: 11634-11639. 10.1073/pnas.93.21.11634.PubMed CentralView ArticlePubMed
- Giorgione JR, Kraayenhof R, Epand RM: Interfacial membrane properties modulate protein kinase C activation: role of the position of acyl chain unsaturation. Biochemistry. 1998, 37: 10956-10960. 10.1021/bi980185a.View ArticlePubMed
- McNeely TB, Rosen G, Londner MV, Turco SJ: Inhibitory effects on protein kinase C activity by lipophosphoglycan fragments and glycosylphosphatidylinositol antigens of the protozoan parasite Leishmania. Biochem J. 1989, 259: 601-604.PubMed CentralView ArticlePubMed
- Turco SJ, Descoteaux A: The lipophosphoglycan of Leishmania parasites. Annu Rev Microbiol. 1992, 46: 65-94. 10.1146/annurev.mi.46.100192.000433.View ArticlePubMed
- Turco SJ: Adversarial relationship between the Leishmania lipophosphoglycan and protein kinase C of host macrophages. Parasite Immunol. 1999, 21: 597-600. 10.1046/j.1365-3024.1999.00266.x.View ArticlePubMed
- Turco SJ, Spath GF, Beverley SM: Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species. Trends Parasitol. 2001, 17: 223-226. 10.1016/S1471-4922(01)01895-5.View ArticlePubMed
- Suffia I, Ferrua B, Stien X, Mograbi B, Marty P, Rousseau D, Fragaki K, Kubar J: A novel Leishmania infantum recombinant antigen which elicits Interleukin 10 production by patient PBMC. Infect Immun. 2000, 68: 630-636. 10.1128/IAI.68.2.630-636.2000.PubMed CentralView ArticlePubMed
- Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N: Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol. 2001, 113: 35-43. 10.1016/S0166-6851(00)00377-7.View ArticlePubMed
- Ferrua B., Le Fichoux Y, Suffia I, Rousseau D, Kubar J: Quantitation of Leishmania infantum in tissues of infected BALB/c mouse by sandwich ELISA. J Immunoassay Immunochem. 2001, 22: 165-181. 10.1081/IAS-100103227.View ArticlePubMed
- Chauchereau A, Loosfelt H, Milgrom E: Phosphorylation of transfected wild type and mutated progesterone receptors. J Biol Chem. 1991, 266: 18280-6.PubMed
- Suffia I, Quaranta JF, Eulalio MC, Ferrua B, Marty P, Le Fichoux Y, Kubar J: Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum. Infect Immun. 1995, 63: 3765-3771.PubMed CentralPubMed
- Watson K, Edwards RJ: HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. Biochem Pharmacol. 1999, 58: 1521-8. 10.1016/S0006-2952(99)00209-9.View ArticlePubMed
- Requena JM, Alonso C, Soto M: Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol Today. 2000, 16: 246-250. 10.1016/S0169-4758(00)01651-3.View ArticlePubMed
- Roux-Lombard P: The interleukin-1 family. Eur Cytokine Netw. 1998, 9: 565-76.PubMed
- Hawn T, Ozinsky A, Underhill D, Buckner F, Akira S, Aderem A: Leishmania major activates IL-1alpha expression in macrophages through aMyD88-dependent pathway. Microbes Infect. 2002, 4: 763-771. 10.1016/S1286-4579(02)01596-4.View ArticlePubMed
- Olivier M, Tanner CE: Susceptibilities of macrophage populations to infection in vitro by Leishmania donovani. Infect Immun. 1987, 55: 467-471.PubMed CentralPubMed
- Proudfoot L, Nikolaev AV, Feng GJ, Wei WQ, Ferguson MA, Brimacombe JS, Liew FY: Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages. Proc Natl Acad Sci. 1996, 93: 10984-10989. 10.1073/pnas.93.20.10984.PubMed CentralView ArticlePubMed
- Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R, Sacks DL: Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med. 1996, 183: 515-526.View ArticlePubMed
- Nandan D, Lo R, Reiner NE: Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani. Infect Immun. 1999, 67: 4055-63.PubMed CentralPubMed
- Forget G, Siminovitch KA, Brochu S, Rivest S, Radzioch D, Olivier M: Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis. Eur J Immunol. 2001, 31: 3185-3196. 10.1002/1521-4141(200111)31:11<3185::AID-IMMU3185>3.0.CO;2-J.View ArticlePubMed
- Bhunia AK, Sarkar D, Das PK: Leishmania donovani attachment stimulates PKC-mediated oxidative events in bone marrow-derived macrophages. J Eukaryot Microbiol. 1996, 43: 373-379.View ArticlePubMed
- Tachado SD, Gerold P, Schwarz R, Novakovic S, McConville M, Schofield L: Signal transduction in macrophages by glycosylphosphatidylinositols of Plasmodium, Trypanosoma, and Leishmania: activation of protein tyrosine kinases and protein kinase C by inositolglycan and diacylglycerol moieties. Proc Natl Acad Sci USA. 1997, 94: 4022-4027. 10.1073/pnas.94.8.4022.PubMed CentralView ArticlePubMed
- Schnur LF, Jacobson RL: Appendix III. Parasitological techniques. In The Leishmaniasis in Biology and Medicine. Edited by: Peters W, Killick-Kendrick R. 1987, London: Academic Press Inc. Limited, 516-518.
- Rousseau D, Le Fichoux Y, Stien X, Suffia I, Ferrua B, Kubar J: Progression of visceral leishmaniasis due to Leishmania infantum in BALB/c mice is markedly slowed by prior infection with Trichinella spiralis. Infect Immun. 1997, 65: 4978-4983.PubMed CentralPubMed
- Ramos A, Maslov DA, Fernandes O, Campbell DA, Simpson L: Detection and identification of human pathogenic Leishmania and Trypanosoma species by hybridization of PCR-amplified mini-exon repeats. Exp Parasitol. 1996, 82: 242-250. 10.1006/expr.1996.0031.View ArticlePubMed
- Rousseau D, Suffia I, Ferrua B, Philip P, Le Fichoux Y, Kubar J: Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniasis in chronically infected BALB/c mice. Eur Cyt Netw. 1998, 9: 655-661.
- Ferrua B, Becker P, Schaffar L, Shaw A, Fehlmann M: Detection of human interleukins 1 alpha and beta at the subpicomolar level by colorimetric sandwich enzyme mmunoassay. J Immunol Methods. 1988, 114: 41-48. 10.1016/0022-1759(88)90151-2.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.